Recibokibart, an anti‐IL‐36 receptor monoclonal antibody, for treating generalized pustular psoriasis: Phase 1b trial

Documenti analoghi

• Severe flare of generalized pustular psoriasis treated with spesolimab, an IL‐36‐directed monoclonal antibody
  di: Valeria Mateeva, et al.
  Pubblicazione: (2024)
• Long‐term remission and normal pregnancy with successful delivery in a patient with generalized pustular psoriasis after spesolimab
  di: Na Wang, et al.
  Pubblicazione: (2024)
• Rapid and sustained resolution in generalized pustular psoriasis with IL‐17A inhibitors required high adherence: a 96‐week analysis in a real‐life setting
  di: Kun Hu, et al.
  Pubblicazione: (2024)
• Biosensing materials for monoclonal antibody detection: An overview
  di: Yuxin Zhang, et al.
  Pubblicazione: (2024)
• Sclerosing cholangitis exacerbated by widespread pustular psoriasis
  di: Akane Ogaya, et al.
  Pubblicazione: (2024)